MaxWell Biosystems was successfully preselected as one of the 10 nominees for the W. A. De Vigier Stiftung award. The Award Ceremony will take place in Solothurn on the 18th of May 2017. The William A. De Vigier foundation provides assistance to young Switzerland entrepreneurs. Since its 28th anniversary, the foundation has distributed over 10 million francs of start-up capital.
MaxWell Biosystems exhibited MaxOne at the BNA 2017 Festival of Neuroscience on April 10-13, 2017 at the ICC, Birmingham. BNA 2017 is one of the largest neuroscience conferences in Europe this year organized by the British Neuroscience Association. Our MaxOne high-resolution technology attracted a lot of interest. And this is not just because of our magic levitation device, but much more because it allows to monitor neuronal activity at various scales, from full networks, to single-cell activity and even subcellular features. We…
After a competitive process, MaxWell Biosystems has been selected as one of the ten members of the Venture Leaders Life Sciences 2017 team. Ten new Swiss innovative start-ups will take part in a startup development program in Boston, Massachusetts on June 11-17, 2017. This “business boosting” week, co-organized by venturelab and swissnex Boston, will enable the selected swiss startups to take the first steps towards their global expansion.
MaxWell Biosystems presented MaxOne at the 96th annual meeting of the Deutsche Physiologische Gesellschaft in Greifswald, Germany on March 16-18, 2017. The German Physiology Society meeting was held at one of the oldest universities in Germany, University of Greifswald (founded 1456). The meeting was participated by researchers working on diverse areas of physiology, including cardiac cell physiology and cellular neuroscience.
MaxWell Biosystems exhibited MaxOne with its newly developed data acquisition unit at the SelectBio Advances in Drug Discovery Conference in Hinxton, Cambridge, UK. It was an exciting meeting, attended by many researchers who are currently screening for efficacy and toxicity using iPS cell lines or developing enabling techniques and technologies for this. Progress in stem cell biology is revolutionizing drug discovery research now; the ability to grow and differentiate stem cell lines is providing a far more relevant model for…
繁體中文
简体中文